177 Lu-FAPI-2286 Radioligand Therapy in Refractory Scalp Melanoma.

Clin Nucl MedSep 10, 2026 (epub)
Case ReportOncology (Medical)Nuclear MedicineRadiology (Diagnostic)

Haniye Elahifard, Mohammad Hadi Samadi, Alireza Bari et al.

✦ AI-curated · Sources linked

Case in brief

A 66-year-old man with inoperable scalp melanoma that had not responded to immunotherapy was assessed for 177Lu-DOTATATE therapy. 99mTc-HYNIC-TOC SPECT/CT showed no uptake in the scalp lesions, so this treatment was not pursued. With subsequent disease progression, 99mTc-FAPI-46 SPECT/CT demonstrated intense uptake, supporting treatment with 177Lu-FAPI-2286. After 4 cycles, all lesions had regressed, and the patient was referred for tumor resection.

What made this case unusual

The lesions were negative on somatostatin-receptor imaging but showed intense uptake on FAPI imaging, which redirected radioligand treatment to 177Lu-FAPI-2286.

Diagnostic / clinical pearl

When 99mTc-HYNIC-TOC imaging shows no uptake in melanoma lesions, 99mTc-FAPI-46 SPECT/CT may identify uptake that can inform consideration of FAPI-targeted radioligand therapy.

Source

PubMed · PMID 42725461

Published in Clin Nucl Med. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Oncology (Medical)

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.